Research Milestones. Biogen Idec shall pay to Sunesis the following amounts within thirty (30) days following the first achievement of the following research milestones with respect to the Collaboration Target:
Research Milestones. (a) As additional consideration for Institute entering into this Agreement and diligently progressing the activities under the Research Collaboration in accordance with this Agreement, Atara will pay to Institute the research milestone payments (each, a “Research Milestone Payment”) set forth in the table below for each Allogeneic CTL Product and/or Autologous Product (as applicable pursuant to the table set forth below) to achieve the corresponding milestone (each, a “Research Milestone”), whether achieved by Institute, Atara or an Affiliate or sublicensee of Atara. The Party achieving such Research Milestone shall promptly notify the other Party in writing of the achievement of any such Research Milestone and Atara shall pay Institute in full the corresponding Research Milestone Payment within [ * ] of such achievement. For clarity, each Research Milestone Payment is payable once only for each Allogeneic CTL Product and once for each Autologous CTL Product, and each Research Milestone Payment is non-refundable, and is not an advance against royalties due to Institute or any other amounts due to Institute. *Milestone payable only once with respect to each Allogeneic Licensed Product to achieve such Milestone. **Milestone payable once for each Allogeneic CTL Product and for each Autologous CTL Product to achieve such Research Milestone.
(b) As consideration for Institute entering into this Agreement and diligently progressing the activities under the Research Collaboration with respect to the Institute [ * ] Programs in accordance with this Agreement, Atara will pay to Institute:
(i) a fixed fee of two million five hundred thousand dollars ($2,500,000) within fifteen (15) business days following the Execution Date (which fee is non-refundable and non-creditable against any other amounts due under this Agreement), and
(ii) the following milestone payments with respect to research and development activities conducted under the [ * ] Programs (each, a “[ * ] Milestone Payment”) set forth in the table below for each [ * ] to achieve the corresponding milestone (each, a “[ * ] Milestone”), whether achieved by Institute, Atara or an Affiliate or sublicensee of Atara. The Party achieving such [ * ] Milestone shall promptly notify the other Party in writing of the achievement of any such [ * ] Milestone and Atara shall pay Institute in full the corresponding [ * ] Milestone Payment within [ * ] days of such achievement. For clarity, each [ * ] Program Milestone Pa...
Research Milestones. In the event that a specific Research Milestone is not met, the Company will have the right upon 30 days prior written notice to Ramot to terminate this Agreement in its entirety. Upon such termination, Company shall pay Ramot for all work performed prior to such termination which has been completed and for all reasonable uncancellable commitments.
Research Milestones. Lilly shall pay Receptos the milestones (the “Research Milestones”) set forth below upon the achievement of each milestone event:
5.2.1 If during the Research Program a Hit satisfies the criteria to be a Structurally Enabled Receptos Hit prior to achievement of a Structurally Enabled Lilly Hit, then, if the Solution related to such Structurally Enabled Receptos Hit then remains confidential (i.e., has not been publicly disclosed other than through any fault or act of Lilly or its Affiliates), Lilly shall pay Receptos a milestone of ***, with such amount payable only one time upon achievement of the first such Structurally Enabled Receptos Hit regardless of the number of Structurally Enabled Receptos Hits; and *** Confidential material redacted and filed separately with the Commission.
5.2.2 If during or subsequent to the Research Program a Hit satisfies the criteria to be a Structurally Enabled Joint Hit or a Structurally Enabled Lilly Hit, then, if the Solution related to such Structurally Enabled Joint Hit or Structurally Enabled Lilly Hit, as applicable, then remains confidential (i.e., has not been publicly disclosed other than through any fault or act of Lilly or its Affiliates), Lilly shall pay Receptos a milestone of *** except that in the event that Lilly has already paid the milestone set forth in Section 5.2.1, such amount paid with respect to such Section 5.2.1 milestone shall be creditable toward the payment of this Section 5.2.2 milestone, with such amount payable only one time upon achievement of the first such Structurally Enabled Joint Hit or Structurally Enabled Lilly Hit regardless of the number of such Structurally Enabled Hits achieved.
5.2.3 The occurrence of Research Milestones shall be confirmed by the JSC. All Research Milestones shall be payable within thirty (30) days after their documented achievement by the JSC. In all events the total amount of Research Milestones payable by Lilly under this Section 5.2 shall not exceed ***.
Research Milestones. Millennium shall pay to Sunesis the following amounts within thirty (30) days following the first achievement of the following research milestones:
Research Milestones. Progress of the Program will be evaluated based on achievement of key milestones (“Milestones”), which are set forth in the Work Plan (Exhibit B). Mahyco shall use its best efforts, consistent with sound and reasonable business practices and judgment, to effect commercialization of Licensed Products as soon as practicable. However, the Milestones may be amended by mutual consent of both Parties, in the event of delays that are beyond the control of Mahyco, including delays for regulatory reasons.
Research Milestones. DS shall pay to Pieris Research Milestone payments [***] within [***] days after the occurrence of the relevant Research Milestone event. With respect to the first DS Target, the following Research Milestone payments shall apply:
Research Milestones. In consideration for the licenses granted herein under the Ambrx Patent Rights and Ambrx Know-How, upon the terms and conditions contained herein, Merck shall pay to Ambrx the following amounts, which shall be non-refundable and shall be non-creditable, with respect to each Selected Target for which Merck achieves the following milestone event during the Term (collectively, the “Research Milestones”): [***] [*** ] [***] [*** ] For clarity, each of the foregoing Research Milestones in this Section 5.4.1 shall be payable [***] The maximum amount payable by Merck under this Section 5.4.1 is [***].
Research Milestones. Research Success Milestone Events Milestone Payments
Research Milestones. Subject to the terms and conditions herein (including this Section 13.4 (Research Milestones) and Section 13.11 (Additional Payment Terms)), and on a Collaboration Degrader Target Set-by-Collaboration Degrader Target Set basis, Seagen shall pay the applicable amount set forth in the table below in this Section 13.4 (Research Milestones) (each a “Research Milestone Payment”) associated with the corresponding milestone event (“Research Milestone Event”) set forth opposite such Research Milestone Payment in the table below, in each case, once upon first achievement of the applicable Research Milestone Event with respect to a Collaboration Degrader Target Set:
(1) [*] [*]
(2) [*] [*]
(3) [*] [*]
(4) [*] [*] Notwithstanding anything to the contrary contained in this Agreement, [*].
